When the COVID-19 pandemic threatened to entirely disrupt clinical trials, decentralized clinical trials (DCT) and direct-to-patient (DTP) models were quickly adopted as a solution. DTP models present opportunities to increase patient convenience and engagement and to simplify recruitment and retention, particularly for rare diseases affecting small, geographically dispersed populations.